Oisín Biotechnologies

About Oisín Biotechnologies

Oisín Biotechnologies is focused on developing genetic medicines to improve health and longevity, targeting age-related conditions through innovative therapies.

Products & Services

Genetic Medicines:Therapies targeting frailty by stimulating muscle growth, selectively killing fat cells, and removing senescent cells.

Fusogenix™ Proteo-Lipid Vehicle (PLV):A non-viral delivery technology enabling extensive extrahepatic biodistribution for DNA and RNA payloads, with safe repeated dosing.

Specialties

Genetic Medicines Age-Related Conditions Non-Viral Delivery Technology Muscle Growth Stimulation Senescent Cell Removal

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2024-07-24 FD: 2024-07-24	1 investors

Series A Latest

2024-07-24

$15.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Scholz

Chief Executive Officer

J

John Lewis, Ph.D.

Chief Science Officer

E

Eric Garcia

Chief Operating Officer

S

Stephen Hilbert

Chief Business Officer

H

Henry Garcia, Ph.D.

Head of Aging R&D

A

Alexandre Gingras, Ph.D.

Head of Preclinical Manufacturing

View 6 more team members with Pro

Unlock Full Team Directory

Recent News